Injesta solution for injections 2.5% ampoules 1 ml. №5


Manufacturer: Ukraine

Amenorrhea, dysfunctional (anovulatory) uterine bleeding; endocrine infertility, including due to insufficiency of the corpus luteum; miscarriage, oligomenorrhea, algodismenorrhea (against the background of hypogonadism).



Injesta Composition
active substance: progesterone;

1 ml of solution contains progesterone in terms of 100% substance, 10 mg or 25 mg;

excipients: 2.5% solution – benzyl benzoate, ethyl oleate; 1% solution – ethyl oleate.

Injesta Dosage form

Basic physical and chemical properties: oily liquid of light green or light yellow color with a specific odor.

Injesta Pharmacotherapeutic group
Gestagens. ATX code G03D A04.

Progesterone is a hormone of the corpus luteum. The drug causes the transformation of the proliferation phase of the uterine mucosa into the secretory phase, which is necessary for the normal implantation of a fertilized egg, and after fertilization contributes to its development. Progesterone also reduces the excitability and contractility of the muscles of the uterus and fallopian tubes, ensures the preservation of pregnancy; stimulates the development of the mammary glands. In small doses it stimulates, and in large doses it inhibits the secretion of gonadotropic hormones. Inhibits the action of aldosterone, which leads to increased secretion of sodium and chlorine in the urine. It has catabolic and immunosuppressive effects.

After intramuscular or subcutaneous injection, it is rapidly and well absorbed from the injection site. Progesterone metabolism occurs in the liver, a small part of it accumulates in the subcutaneous fatty tissue. The main product of the conversion of progesterone is the biologically active pregnanediol. Pregnanediol, after conjugation with glucuronic acid, passes from the liver into the bloodstream, and then into the urine. Less progesterone is converted to pregnanolol and pregnandione. All progesterone metabolites excreted in the urine are inactive.

Amenorrhea, dysfunctional (anovulatory) uterine bleeding; endocrine infertility, including due to insufficiency of the corpus luteum; miscarriage, oligomenorrhea, algomenorrhea (against the background of hypogonadism).

Liver disease, liver dysfunction, hepatitis, hepatic and renal failure, cholestatic jaundice during pregnancy (history), benign hyperbilirubinemia; neoplasms of the mammary gland and genitals; tachycardia, a tendency to thrombosis, active venous or arterial thromboembolism, severe thrombophlebitis, or a history of these conditions; nervous disorders with symptoms of depression; porphyria; pregnancy after the 36th week; a history of ectopic pregnancy or missed pregnancy; vaginal bleeding of unknown origin, condition after abortion; hypersensitivity to the components of the drug.

Interaction with other medicinal products and other types of interactions
Ingesta weakens the effect of drugs that stimulate the contraction of the myometrium (oxytocin, pituitrin), anabolic steroids (retabolil, nerobol), pituitary gonadotropic hormones. When interacting with oxytocin, the lactogenic effect decreases. Enhances the effect of diuretics, antihypertensive drugs, immunosuppressants, bromocriptine and systemic coagulants. Reduces the effectiveness of anticoagulants. The action of Ingesta decreases with the simultaneous use of barbiturates. Changes the effects of hypoglycemic agents. With simultaneous use with inducers of hepatic enzymes, it is possible to increase or decrease the concentration of Ingesta in the blood plasma.